Kevin Hazard, MD
Endocrinology, Diabetes & Metabolism · Springfield, ILNPI 1881652089
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Abbott at 38.0% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in IL, where the typical reported total is $721.
Across 53 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$340
- Novartis$153
- AbbVie$82
- Novo Nordisk$43
- Xeris Pharmaceuticals, Inc.$40
- Sanofi-aventis U.S. LLC$35
- plus $201 from 11 others
Across 17 payments — averaging $2550.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Senseonics, Incorporated$43K
What the payments were for
- Food & beverage$894100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 24 | $340 |
| Novartis | 8 | $153 |
| AbbVie | 5 | $82 |
| Novo Nordisk | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Sanofi-aventis U.S. LLC | 1 | $35 |
| Medtronic | 1 | $30 |
| Recor Medical Inc | 1 | $23 |
| Dexcom, Inc. | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Echosens North America, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Itamar Medical Inc | 1 | $14 |
| BETA Bionics, Inc. | 1 | $12 |
How this compares
$894 in reported general payments places this provider in the 50th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 469 | $721,582 |
| MounjaroTirzepatide | 431 | $534,022 |
| JardianceEmpagliflozin | 351 | $407,995 |
| FarxigaDapagliflozin Propanediol | 193 | $190,994 |
| TrulicityDulaglutide | 114 | $152,070 |
| ForteoTeriparatide | 27 | $116,693 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 51 | $105,355 |
| GenotropinSomatropin | 18 | $104,461 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 184 | $102,030 |
| Novolog FlexpenInsulin Aspart | 227 | $83,707 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 52 | $78,500 |
| Teriparatide | 25 | $78,229 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 465 | $74,020 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $61,864 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 52 | $59,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Tresiba | $43 | $807,996590 claims |
| Sanofi-aventis U.S. LLCLantus, Admelog | $35 | $28,807109 claims |
| AbbVieSynthroid | $82 | $19,439185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Springfield
- Marina RussoSpringfield$19K
- Gabriel UwaifoSpringfield$11K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.